Page 123 - Read Online

Thonglert et al. Hepatoma Res 2023;9:40 https://dx.doi.org/10.20517/2394-5079.2023.47 Page 23 of 23

84. Ader I, Delmas C, Skuli N, et al. Preclinical evidence that SSR128129E--a novel small-molecule multi-fibroblast growth factor
receptor blocker--radiosensitises human glioblastoma. Eur J Cancer 2014;50:2351-9. DOI
85. Verstraete M, Debucquoy A, Gonnissen A, et al. In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR
inhibitor (JNJ-42756493) for rectal cancer. BMC Cancer 2015;15:946. DOI PubMed PMC
86. Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in
cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol 2019;10:751-65. DOI PubMed PMC
87. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-44. DOI
PubMed PMC
88. Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy):
a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2020;21:796-807. DOI PubMed PMC
89. Tran AN, Lai A, Li S, et al. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial
quantitative MR volumetry. Neuro Oncol 2014;16:414-20. DOI PubMed PMC
90. Wang Y, Wild AT, Turcan S, et al. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas
and cholangiocarcinomas. Sci Adv 2020;6:eaaz3221. DOI PubMed PMC
91. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Available from: https://www.fda.gov/drugs/
resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication [Last
accessed on 15 Aug 2023].
92. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Available from: https://www.fda.gov/drugs/drug-
approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors [Last accessed on 15 Aug 2023].
93. Silva VW, Askan G, Daniel TD, et al. Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. Chin Clin
Oncol 2016;5:62. DOI
94. Israel MA, Danziger N, McGregor KA, et al. Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type,
ancestry, and testing patterns. Oncologist 2021;26:787-96. DOI PubMed PMC
95. Wang Y, Deng W, Li N, et al. Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future
directions. Front Pharmacol 2018;9:185. DOI PubMed PMC
96. Liu ZL, Liu X, Peng H, et al. Anti-PD-1 immunotherapy and radiotherapy for stage IV intrahepatic cholangiocarcinoma: a case report.
Front Med 2020;7:368. DOI PubMed PMC
97. Zhao Q, Chen Y, Du S, et al. Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar
cholangiocarcinoma: reflection from four cases. Cancer Biol Ther 2021;22:175-83. DOI PubMed PMC
98. Liu X, Yao J, Song L, Zhang S, Huang T, Li Y. Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low
TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade. J Immunother Cancer
2019;7:204. DOI PubMed PMC
99. Mondini M, Levy A, Meziani L, Milliat F, Deutsch E. Radiotherapy-immunotherapy combinations-perspectives and challenges. Mol
Oncol 2020;14:1529-37. DOI PubMed PMC